[go: up one dir, main page]

NO20091301L - Nye aminopyridinderivater med aurora A selektiv inhiberende aktivitet - Google Patents

Nye aminopyridinderivater med aurora A selektiv inhiberende aktivitet

Info

Publication number
NO20091301L
NO20091301L NO20091301A NO20091301A NO20091301L NO 20091301 L NO20091301 L NO 20091301L NO 20091301 A NO20091301 A NO 20091301A NO 20091301 A NO20091301 A NO 20091301A NO 20091301 L NO20091301 L NO 20091301L
Authority
NO
Norway
Prior art keywords
aurora
inhibitory activity
selective inhibitory
aminopyridine derivatives
novel aminopyridine
Prior art date
Application number
NO20091301A
Other languages
English (en)
Inventor
Katsumasa Nonoshita
Mitsuru Ohkubo
Tetsuya Kato
Nobuhiko Kawanishi
Takashi Mita
Yoshikazu Iwasawa
Kouta Masutani
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO20091301L publication Critical patent/NO20091301L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse gjelder en forbindelse med den generelle formel I,. hvori: Ri er et hydrogenatom, F, CN, osv.; Rer O, S, SO, S0, osv.;. Rer fenyl som kan være substituert; Xer CH, N, osv.; W er følgende rest:. hvori: Wi, Wog Wuavhengig av hverandre er CH, N, osv., eller et farmasøytisk salt eller en farmasøytisk akseptabel ester derav.
NO20091301A 2006-08-31 2009-03-30 Nye aminopyridinderivater med aurora A selektiv inhiberende aktivitet NO20091301L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006236472 2006-08-31
US92608607P 2007-04-25 2007-04-25
PCT/JP2007/067250 WO2008026768A1 (en) 2006-08-31 2007-08-29 Novel aminopyridine derivatives having aurora a selective inhibitory action

Publications (1)

Publication Number Publication Date
NO20091301L true NO20091301L (no) 2009-04-30

Family

ID=39136042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091301A NO20091301L (no) 2006-08-31 2009-03-30 Nye aminopyridinderivater med aurora A selektiv inhiberende aktivitet

Country Status (27)

Country Link
US (2) US7915263B2 (no)
EP (2) EP2061782A4 (no)
JP (3) JP2008081492A (no)
KR (1) KR20090055562A (no)
CN (1) CN101528731B (no)
AR (1) AR062585A1 (no)
AU (1) AU2007289609B2 (no)
CA (1) CA2657469C (no)
CL (1) CL2007002519A1 (no)
CO (1) CO6190529A2 (no)
CR (1) CR10553A (no)
EC (1) ECSP099062A (no)
ES (1) ES2389515T3 (no)
GT (1) GT200900008A (no)
HN (1) HN2009000113A (no)
IL (1) IL196497A0 (no)
MA (1) MA30719B1 (no)
MX (1) MX2009000390A (no)
NO (1) NO20091301L (no)
NZ (1) NZ574081A (no)
PE (1) PE20080835A1 (no)
RU (1) RU2437880C2 (no)
SV (1) SV2009003152A (no)
TW (1) TW200817363A (no)
UA (1) UA95972C2 (no)
WO (2) WO2008026768A1 (no)
ZA (1) ZA200900126B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519136B2 (en) 2008-02-22 2013-08-27 Msd K.K. Aminopyridine derivatives having aurora a selective inhibitory action
EP2262813A4 (en) * 2008-03-31 2011-10-12 Sun Pharmaceutical Ind Ltd IMPROVED PROCESS FOR THE PREPARATION OF MORPHINANE ANALOGS
WO2010009985A2 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US9567318B2 (en) * 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
MX375924B (es) 2014-05-13 2025-03-07 Memorial Sloan Kettering Cancer Center Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo.
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
CN107251007B (zh) * 2015-03-25 2021-10-01 英特尔公司 集群计算服务确保装置和方法
CN108250191B (zh) * 2018-03-15 2020-10-20 兰州大学 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
US20250249019A1 (en) 2022-04-08 2025-08-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
WO1992005785A1 (en) 1990-09-28 1992-04-16 Smithkline Beecham Corporation Water soluble camptothecin analogues, processes and methods
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
DE60023926T2 (de) * 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
MXPA03005608A (es) * 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
RU2332415C2 (ru) * 2001-04-27 2008-08-27 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, полезные в качестве ингибиторов протеинкиназы
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
EP1754706A4 (en) * 2004-05-21 2010-08-18 Banyu Pharma Co Ltd SELECTIVE INHIBITORS FOR CDK4 AND CDK6 WITH AMINOTHIAZOLSKELETT
WO2006046734A2 (ja) * 2004-10-29 2006-05-04 Banyu Pharma Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US20060160869A1 (en) 2005-01-05 2006-07-20 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CN101166732B (zh) * 2005-04-28 2013-04-17 田边三菱制药株式会社 氰基吡啶衍生物及其作为药物的应用
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives

Also Published As

Publication number Publication date
JP4466782B2 (ja) 2010-05-26
CA2657469C (en) 2013-07-02
SV2009003152A (es) 2009-04-28
EP2062887A4 (en) 2010-03-31
NZ574081A (en) 2011-08-26
ECSP099062A (es) 2009-02-27
CL2007002519A1 (es) 2008-02-08
ZA200900126B (en) 2010-01-27
PE20080835A1 (es) 2008-06-14
JP2008081492A (ja) 2008-04-10
US20080058347A1 (en) 2008-03-06
AU2007289609B2 (en) 2012-02-02
EP2061782A1 (en) 2009-05-27
HN2009000113A (es) 2014-01-06
JPWO2008026769A1 (ja) 2010-01-21
CN101528731A (zh) 2009-09-09
EP2062887B1 (en) 2012-07-04
CR10553A (es) 2009-06-28
IL196497A0 (en) 2009-09-22
EP2061782A4 (en) 2010-03-31
EP2062887A1 (en) 2009-05-27
ES2389515T3 (es) 2012-10-26
US7915263B2 (en) 2011-03-29
WO2008026768A1 (en) 2008-03-06
CN101528731B (zh) 2014-05-07
JP5256168B2 (ja) 2013-08-07
MX2009000390A (es) 2009-01-29
KR20090055562A (ko) 2009-06-02
TW200817363A (en) 2008-04-16
UA95972C2 (ru) 2011-09-26
CA2657469A1 (en) 2008-03-06
AU2007289609A1 (en) 2008-03-06
AR062585A1 (es) 2008-11-19
CO6190529A2 (es) 2010-08-19
MA30719B1 (fr) 2009-09-01
WO2008026769A1 (en) 2008-03-06
RU2009111599A (ru) 2010-10-10
RU2437880C2 (ru) 2011-12-27
GT200900008A (es) 2010-10-04
JP2010047602A (ja) 2010-03-04
US20100016335A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
NO20091301L (no) Nye aminopyridinderivater med aurora A selektiv inhiberende aktivitet
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
NO20082346L (no) Hydrazonderivater og anvendelser derav
JO2791B1 (en) Acid secretion inhibitor
NO20083434L (no) Benzamid- og heteroarenderivater
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
MY152972A (en) Azabicyclo compound and salt thereof
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
WO2008108380A3 (en) Pyrrole compounds
MY177250A (en) Novel nicotinamide derivative or salt thereof
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
WO2006072599A3 (en) Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
NO20082934L (no) Antivirale nukleotider
CY1109532T1 (el) Παραγωγα ινδολο 1-οξεικου οξεος με pgd2 ανταγωνιστικη δραστικοτητα
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20076648L (no) Novel thiophene derivatives
NO20081217L (no) Nye benzotiazolonderivater
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
NO20085107L (no) Spirosykliske nitriler som proteaseinhibitorer
MY169179A (en) Novel piperidine compound or salt thereof
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application